WARNING:
JavaScript is turned OFF. None of the links on this concept map will
work until it is reactivated.
If you need help turning JavaScript On, click here.
This Concept Map, created with IHMC CmapTools, has information related to: Breast Cancer Endpoints - Master Primary m8, Effusion/ascites has_value >Yes >No, Neoadjuvant setting has_component Overall Survival (OS), FDA Criteria for Efficacy endpoints for Breast Cancer treatment has_pertinent_information Tumor Biopsy, Measurable lesions has_location Anatomical region, Main concept groups (e.g. Primary endpoints) are denoted by Larger bold font with thicker outline, Lymph node examination measured_over Quantity of nodes, Disease present is_measured_from Breast tumor microscopic assessment, Adjuvant setting has_component Disease free survival (DFS), Follow-up evaluation has_timepoint Date of progression, New disease/lesions is_classified_by >Local >Regional >Distant, Baseline assessment has_timepoint Date of evaluation, FDA Criteria for Efficacy endpoints for Breast Cancer treatment has_pertinent_information Cancer stage, Tumor assessment is_derived_from RECIST v1.1 criteria, Target lesion has_component Quantitative assessment, Neoadjuvant setting has_component Pathologic complete response (pCR), Cystic lesion has_value >Simple >Complex, Demographics/Medical history has_components >Age >Ethnicity >Pregnancy status >BRCA1/2 mutation >Gene expression >Co-morbidities, Concepts (e.g. CRF:pCR:Surgical margins are denoted by solid round-edged rectangle, Other lymph nodes include_ evaluation_of Other lymph node dissection, Lymph node examination include_evaluation_of Size of largest lymph node metasteses